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Cryptosporidium is a widely distributed enteric parasite that has an increasingly appreciated
pathogenic role, particularly in pediatric diarrhea. While cryptosporidiosis has likely affected
humanity for millennia, its recent “emergence” is largely the result of discoveries made
through major epidemiologic studies in the past decade. There is no vaccine, and the only
approved medicine, nitazoxanide, has been shown to have efficacy limitations in several
patient groups known to be at elevated risk of disease. In order to help frontline health work-
ers, policymakers, and other stakeholders translate our current understanding of cryptospo-
ridiosis into actionable guidance to address the disease, we sought to assess salient issues
relating to clinical management of cryptosporidiosis drawing from a review of the literature
and our own field-based practice. This exercise is meant to help inform health system strate-
gies for improving access to current treatments, to highlight recent achievements and out-
standing knowledge and clinical practice gaps, and to help guide research activities for new
anti-Cryptosporidium therapies.
Introduction
Diarrhea has long been one of humanity’s gravest health problems. In 2017, there were greater
than 6 billion incident episodes and 1.5 million deaths from diarrhea, making it the fifth lead-
ing cause of years of life lost [1,2]. The clinical impact is particularly severe in children under
age 5, in whom diarrhea is the third most common cause of mortality (behind pneumonia and
preterm birth complications) with nearly half a million attributable deaths each year [3,4]. For-
tunately, mortality due to diarrhea has decreased, from more than 2.5 million overall deaths
and 1.6 million child deaths in 1990, thanks in part to oral rehydration therapy and various
public health advances including rotavirus vaccine and improved water and sanitation [2,5,6].
While assuring universal access to these proven interventions remains an urgent priority,
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there is also a need to identify new paths to tackling specific aspects of diarrheal disease in
order to maintain, or ideally accelerate, progress.
Over the past decade, a number of large, multicountry studies have cast light on the global
epidemiology of pediatric diarrhea in the modern era. A persistent area of uncertainty in man-
agement of diarrhea relates to appropriate use of targeted therapies. Dozens of enteric organ-
isms (including bacteria, viruses, and protozoa) induce diarrhea and, while most episodes are
self-limiting or can be successfully managed with supportive care, there are recognized clinical
scenarios where pathogen-specific treatment is indicated (Table 1). If novel data demonstrate
that certain additional patient populations may benefit from targeted treatment approaches,
then translating evidence into clear and actionable guidance for frontline health workers pro-
vides an opportunity to further reduce preventable diarrhea-associated harm.
Cryptosporidium is a widely distributed enteric parasite that has an increasingly appreciated
pathogenic role, particularly in pediatric diarrhea. In the 1980s, cryptosporidiosis was recog-
nized to be a serious enteric infection in people living with HIV/AIDS (PLWHA) and indeed
was one of the original acquired immunodeficiency syndrome (AIDS)-defining illnesses [7,8].
Since that time, Cryptosporidium has been implicated in acute or chronic diarrhea in varied
patient populations and in diverse geographies, especially among children in low- and middle-
income countries (LMICs) [9].
There is no vaccine for cryptosporidiosis, and the single approved medicine, nitazoxanide,
appears to be infrequently used, presumably due to a mix of factors including perception of
limited efficacy (small-scale clinical studies in sub-Saharan Africa demonstrated poor
responses in malnourished children with HIV infection) [10,11], diagnostic challenges
(resources are largely absent in clinical settings in LMICs to identify Cryptosporidium oocysts
by microscopy or point-of-care rapid diagnostic tests), and dearth of guidance for addressing
cryptosporidiosis in standard treatment guidelines published by international and national
authorities [10–12]. Given that cryptosporidiosis is rarely specifically treated, practitioners in
regions where it is highly prevalent may naturally have limited awareness of Cryptosporidium
as a potential pathogen and restricted understanding of when anti-Cryptosporidium therapy
may have clinical benefit.
Table 1. Clinical scenarios where pathogen- or syndrome-specific treatment is applied for diarrheal disease. This table summarizes relevant aspects of treatment
guidelines published by the World Health Organization and other groups. It is acknowledged that the evidence base for some interventions is variable and the use of these
therapies in practice is often country- and resource-dependent.
Disease Clinical scenario Typical therapeutic interventions
Amoebiasis • Bloody diarrhea in severely malnourished children with Entamoeba histolytica or bloody
diarrhea that continues after treatment for Shigella [13,14]
• Patients with trophozoites of E. histolytica containing red blood cells identified in fresh
feces [15]
Metronidazole, tinidazole
Cholera • Adults and children over 5 years with severe dehydration from acute watery diarrhea
(usually with vomiting) [14,15]






Hospital- or community-acquired diarrheal disease [16] Oral vancomycin, metronidazole
Giardiasis • Severely malnourished children with Giardia [13,17]
• Children with chronic, malabsorptive, nonbloody diarrhea without fever
• Adults and children with stool microscopy that is positive for cysts or trophozoites [14]
Metronidazole, tinidazole, ornidazole,
nitaxozanide
Shigellosis Bloody diarrhea in severely malnourished children [13,18] Ampicillin, cotrimoxazole, nalidixic acid
Bloody diarrhea in adults and children, irrespective of nutritional status [14,18] Azithromycin, ceftriaxone, ciprofloxacin
Other clinical
scenarios
Bloody diarrhea in HIV–positive and HIV–exposed infants and children [19] Ciprofloxacin
Diarrhea in returned travelers to low-income countries [20] Ciprofloxacin, azithromycin
https://doi.org/10.1371/journal.pntd.0009057.t001
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As a group of physicians and scientists engaged on the problem of diarrheal diseases in
LMICs, along with researchers conducting drug discovery for new anti-Cryptosporidium medi-
cines, we sought to plainly characterize salient issues relating to therapies for cryptosporidiosis.
Specifically, we compiled from contemporary literature and from firsthand experience a
description of the populations most affected by cryptosporidiosis. We then reviewed the rele-
vance of nitazoxanide in those patients and examined the clinical settings in which an anti-
Cryptosporidium medicine is needed. Finally, we summarized the expected characteristics
and benefits of an ideal therapeutic and assessed the landscape of anti-Cryptosporidium thera-
pies in the drug development pipeline. This exercise is meant to help inform health system
strategies for improving access to nitazoxanide in clinical circumstances where it might be
indicated, to highlight key knowledge and clinical practice gaps relating to Cryptosporidium’s
influence on human health, and to help guide research activities for new anti-Cryptosporidium
therapies.
A brief history of cryptosporidiosis
Cryptosporidium species are ubiquitous Apicomplexan protozoa phylogenetically related to
Plasmodium (the agent of malaria), which are thought to have evolved into existence on the
order of 600 million years ago [21]. However, while malaria has long been recognized to be an
ancient scourge, the impact of Cryptosporidium on human health has only been appreciated in
recent history. Cryptosporidium was first observed in mice in 1907, and its presence as a patho-
gen in young cows was described in 1971 [22,23]. The first human infection was reported in
1975 (a 3-year-old farm girl from rural Tennessee with severe diarrhea, vomiting, and abdomi-
nal pain) [24]. Shortly thereafter, as the HIV/AIDS epidemic surfaced, Cryptosporidium was
associated with severe, sometimes fatal diarrhea in immunocompromised individuals [25,26].
The first reports of cryptosporidiosis in Africa came from Liberia and Rwanda beginning in
1984 [27,28], and since then, it has been described on every continent (including Antarctica)
in both low- and high-resource countries.
More than 15 species of Cryptosporidium cause human infection with 2 species accounting
for approximately 90% of human infections: Cryptosporidium hominis (approximately 80%)
and Cryptosporidium parvum (approximately 10%) [29]. Cryptosporidium is hardy. The
oocysts can survive in the environment for months and are resistant to chlorine concentrations
that are normally used for water treatment [30,31]. Transmission between humans takes place
via waterborne, foodborne, and nosocomial routes; there is also anthroponotic and zoonotic
spread. As few as 10 oocysts can cause clinically apparent infection in healthy adults [32]. The
pathogenicity of Cryptosporidium seems to be influenced by the parasite species and the type,
age, and immune status of the infected host [33]. As described in greater detail in the sections
below, it is increasingly suspected that both symptomatic as well as asymptomatic infections
have negative implications on human health.
Looking ahead, there are signs that the burden of cryptosporidiosis globally could rise even
more due to changes in climate, urbanization (facilitating increases in person-to-person trans-
mission), and predicted population growth patterns. Warmer temperatures and changing
rainfall patterns may cause increased contamination of water bodies, greater transmission, and
emergence of disease in new geographies [34]. Modeling exercises show Cryptosporidium
emission to the environment could increase up to 70% by the year 2050 in some regions [35].
Moreover, impacts of climate change on food security and nutritional status may further
increase susceptibility of vulnerable populations, especially children, to cryptosporidiosis and
other parasitic infections [36,37].
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Patient groups in need of an anti-Cryptosporidium therapeutic
There is currently compelling evidence of unmet therapeutic need for enteric cryptosporidiosis
in 3 patient groups specifically: young children aged 0 to 24 months in LMICs, malnourished
children under age 5, and immunosuppressed individuals of any age. These patient groups
appear to be at elevated risk of acquiring Cryptosporidium infection, and, when infected, stud-
ies have shown patients in these populations to have poorer clinical outcomes. In addition,
people in any global setting that are affected by outbreaks may be candidates for Cryptosporid-
ium-specific therapy. A brief review of the literature pertaining to these patient groups is pre-
sented below and summarized in Table 2. Also discussed are the theoretical cases for empiric
therapy and mass drug administration.
Young children aged 0 to 24 months in LMICs
In the past decade, Cryptosporidium has emerged to be one of the most important diarrhea-
causing enteric pathogens associated with severe morbidity and mortality in immunocompe-
tent young children under 2 years of age. The strongest evidence comes from 2 major prospec-
tive studies, the Global Enteric Multicenter Study (GEMS) [38] and the Etiology, Risk Factors,
Table 2. Summary of use-case scenarios for an anti-Cryptosporidium therapeutic.




7.5 million cases and 200,000 deaths
annually (in Africa and Asia) [29]
Primary, secondary, and tertiary
health facilities in LMICs
Diagnosis-based treatment Not approved in
children under 12
months
Empiric treatment in high-risk
populations where diagnostic
tools are not available
Insufficient evidence
and guidelines
Community-based treatment Mass drug administration in
seasons with high prevalence
Insufficient evidence
and guidelines
Malnourished children Estimated 50 million wasted children
globally [96]; recent studies indicate 10%–
20% prevalence of cryptosporidiosis in
children with acute malnutrition [54–56]
Primary, secondary, and tertiary
health facilities in LMICs;




in typical clinical settings often
limit practicality of this
approach)
Poorly effective (i.e., less
than 50% efficacious)
[10]
Empiric treatment in high-risk
populations where diagnostic







Estimates range from 5%–50% of
PLWHA and up to 30% of solid organ
transplant recipients [80,84,97,98]
Primary, secondary, and tertiary
health facilities in LMICs; HIV/
AIDS treatment programs;
transplant centers in any global
setting
Diagnosis-based treatment Poorly or noneffective
for PLWHA [10,11,99]
Empiric treatment in high-risk
populations where diagnostic






Outbreaks Hundreds of outbreaks reported annually
in high-income countries that likely affect
thousands of individuals [100,101]; poor
data availability for outbreak reporting in
LMICs
Health facilities involved in
outbreak response




diagnostic tools are not available
Insufficient evidence
and guidelines




LMICs, low- and middle-income countries; PLWHA, people living with HIV/AIDS.
https://doi.org/10.1371/journal.pntd.0009057.t002
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and Interactions of Enteric Infections and Malnutrition and the Consequences for Child
Health and Development Project (MAL-ED) [39]. In addition, various sub-analyses and meta-
analyses utilizing data from those studies have further reported on the burden of cryptosporid-
iosis. The findings from GEMS and MAL-ED are also consistent with numerous recent reports
from smaller scale investigations in Africa and Asia [40,41].
The original GEMS study (GEMS-1), which took place from 2007 to 2011, involved nearly
10,000 children aged 0 to 59 months who presented at health facilities with moderate-to-severe
diarrhea (MSD) and more than 13,000 control children without diarrhea at 4 sites in Africa
(The Gambia, Kenya, Mali, and Mozambique) and 3 sites in Asia (Bangladesh, India, and Paki-
stan) [38]. The majority of subjects with MSD was aged 0 to 24 months. Cryptosporidium was
the second most common cause of MSD in the first year of life (behind rotavirus) and the
third most common cause in the second year of life (behind rotavirus and Shigella). A follow-
on study in 2011 to 2012, GEMS-1A, studied less-severe diarrhea (LSD) at 6 sites in The Gam-
bia, Mali, Mozambique, Bangladesh, India, and Pakistan [42]. Again, Cryptosporidium was
identified to be a main pathogen—specifically, it was the third most common cause of LSD in
the first year of life (behind rotavirus and enterotoxigenic E. coli) and the fourth most common
cause of LSD in the second year of life (behind rotavirus, enterotoxigenic E. coli, and H. pylori).
Extrapolating the results from GEMS-1 and GEMS-1A across sub-Saharan Africa and Asia
predicted more than 7.5 million cases and 200,000 deaths attributable to cryptosporidiosis
annually in those regions in children aged 0 to 24 months [29]. An analysis across all GEMS
sites revealed Cryptosporidium to be an independent risk factor for mortality in toddlers aged
12 to 24 months, and a focused sub-analysis at the Mozambique site found Cryptosporidium to
be 1 of only 2 pathogens (the other was enterotoxigenic E. coli) independently associated with
increased risk of death [43,44]. It is worth noting that the methodology of GEMS involved lim-
iting recruitment to the same number of children per week throughout the study period. Thus,
seasonal variations in disease burden, which are likely relevant in cryptosporidiosis, may have
been underestimated due to the study inclusion strategy.
MAL-ED was a birth cohort community surveillance study that took place between 2009
and 2014 and involved more than 2,000 children aged 0 to 24 months at urban and rural sites
in Africa (South Africa, Tanzania), Asia (Bangladesh, India, Nepal, Pakistan), and South
America (Brazil, Peru) [39]. Across all sites, Cryptosporidium was 1 of 4 pathogens most often
associated with diarrhea in the first year of life (along with Campylobacter, norovirus, and rota-
virus) and 1 of 6 pathogens most often linked with diarrhea in the second year of life (along
with astrovirus, heat-labile enterotoxigenic E. coli, heat-stabile enterotoxigenic E. coli, norovi-
rus, and Shigella). Heterogeneity in pathogen distributions was observed between study sites
and the burden of Cryptosporidium varied. For example, Cryptosporidium was the most com-
mon pathogen associated with diarrhea at the Pakistan site in children aged 0 to 24 months.
The Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) from the
Institute of Health Metrics and Evaluation (IHME) included a systematic analysis of diarrheal
diseases, incorporating data from GEMS [4]. That analysis did not stratify by age in the first 5
years of life, and so the burden of disease in children aged 0 to 24 months specifically was not
available. In all under-fives, Cryptosporidium was reported to be the second leading cause of
diarrhea-related deaths (after rotavirus), responsible for an estimated 60,400 deaths.
Children under 5 years of age with malnutrition
Diarrhea is a common comorbidity in children with malnutrition. Two prominent consider-
ations that concern the interplay of cryptosporidiosis and malnutrition are the implications
for children who are acutely malnourished (i.e., children with wasting; characterized by a low
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weight-for-age) and those with linear growth faltering (i.e., children that are stunted; charac-
terized by a low height-for-age). Indeed, a “vicious cycle” is described between malnutrition
and Cryptosporidium infection whereby chronic cryptosporidiosis is associated with linear
growth impairment at the same time children with acute malnutrition may be predisposed to
enteric Cryptosporidium infection [45,46].
In our own experience treating malnourished children in sub-Saharan Africa (SS, BA, PK),
we have found that clinical management of acute watery diarrhea due to cryptosporidiosis is
particularly difficult in children with wasting who have limited physiologic capacity to adapt
to shifts in fluid and electrolyte balance. In these patients, it can be challenging to successfully
rehydrate by oral routes, which is recommended when possible in most protocols. Using high
volumes of oral rehydration solution specifically formulated for acutely malnourished children
runs the risk of iatrogenic hyponatremia and cerebral edema [47,48], whereas parenteral fluid
replacement in acutely malnourished children risks fluid overload and potentially fatal high-
output heart failure [49]. These experiences at the bedside in caring for patients with crypto-
sporidiosis are reflected in observational studies that suggest an elevated risk of death in
acutely malnourished children that are infected with Cryptosporidium. At a malnutrition ward
in Zambia, 35% of children with cryptosporidiosis died compared to 14% without Cryptospo-
ridium infection [49]. In Chad, the mortality rate in children with severe acute malnutrition
and cryptosporidiosis was nearly twice that in children with malnutrition alone [50]. Similar
results were reported in Uganda and, through modeling, a recent GEMS sub-analysis showed
a trend toward association of cryptosporidiosis with additional risk of death in children with
acute malnutrition [51,52].
The clinical impact of cryptosporidiosis in acutely malnourished children is concerning
because the prevalence of infection in that population appears to be significant. In Bangladesh,
the incidence of Cryptosporidium-induced diarrhea in malnourished children was 12.2 epi-
sodes per 100 child years compared to 7.3 in children without malnutrition (risk ratio 1.7; 95%
confidence interval 1.1 to 2.6) [53]. Cryptosporidium was detected by PCR in approximately
20% of over 300 children with severe acute malnutrition in Malawi and Kenya (a comparison
with the infection rate in well-nourished children was not reported) [54]. At sites in Ghana
and India, approximately 10% of children with acute malnutrition were infected with Crypto-
sporidium as detected by PCR, microscopy, and ELISA, compared to 5% (Ghana) and 7%
(India) in well-nourished children, though these differences were not statistically significant
[55,56]. Other studies also reported a higher, albeit nonsignificant, incidence of cryptosporidi-
osis in malnourished children compared to those without malnutrition [52,57,58].
Stunting is a major global health problem affecting a staggering 23% of children in LMICs,
which is largely attributed to a confluence of factors that includes nutrition deficiencies and
enteric infection in impoverished environments [59,60]. Numerous cross-sectional studies, as
well as a meta-analysis conducted as part of the Global Burden of Disease Study, associate
Cryptosporidium infection with stunting [1,61]. Moreover, prospective investigations on 3
continents (Africa, Asia, and South America) have shown infection with Cryptosporidium in
infancy and young childhood to be causal in stunting [41,62–65]. This relationship was addi-
tionally demonstrated through sub-analyses of longitudinal data collected through MAL-ED,
which showed linear growth faltering at 2 of 8 sites (in India and Bangladesh) as well as a
reduction in length-for-age at 2 years across 7 sites through a longitudinal modeling exercise
[66,67].
Both asymptomatic (i.e., subclinical; without diarrhea) and symptomatic (i.e., associated
with diarrhea) infections have been linked with stunting. In symptomatic infections, the risk
appears to increase commensurate with increasing numbers of diarrheal episodes [62,63,65].
The long-term complications of Cryptosporidium infection at an early age may not be limited
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to growth faltering—impairments in general physical fitness and cognition later in childhood
have also been recorded [68,69]. To date, the findings that demonstrate a potential role of
cryptosporidiosis with impairments in growth and development have not been translated into
clinical interventions; no studies have yet been conducted to assess the impact of treating
enteric Cryptosporidium in young childhood to reduce the prevalence of stunting or other
chronic sequalae.
Immunocompromised children and adults
The increased morbidity and mortality imposed by Cryptosporidium [70,71] has important
implications for the estimated 36 million PLWHA, more than 30 million of whom reside in
LMICs [72,73]. Historically, the importance of Cryptosporidium as a human pathogen origi-
nated in the early 1980s as an opportunistic infection, particularly among PLWHA [8].
Cryptosporidiosis remains an advanced HIV/AIDS clinical staging criterion [74]. Cryptospo-
ridium is among the most common intestinal parasites identified among children and adults
living with HIV, and in many studies is the leading enteric parasitosis in those populations.
Cryptosporidiosis may also be complicated by extraintestinal disease in immunocompromised
patients (e.g., biliary tract and pulmonary infection) and, although they are rare, these compli-
cations are frequently fatal.
Recent investigations report that Cryptosporidium infection ranges between 5% to 50% of
PLWHA in Africa, Asia, and the Americas [75–79]. A systematic review involving more than
100 studies estimated the overall prevalence of Cryptosporidium in this population to be 14%
[80]. Absence of antiretroviral therapy and low CD4+ counts are known risk factors for
increased incidence of cryptosporidiosis in PLWHA [81,82].
Cryptosporidium infection has also been reported as a leading cause of diarrhea in solid
organ transplant (SOT) recipients receiving immunosuppressive therapies [83]. Cryptosporid-
ium-induced diarrhea has been reported to occur in up to 30% of SOT recipients and is char-
acterized by prolonged severe diarrhea, fluid and electrolyte depletion, and organ failure if
untreated [83]. In a cohort of SOT patients followed in France, the incidence of cryptosporidi-
osis was highest in the first 6 months after transplantation [84]. Investigators recommended
systematic screening for cryptosporidiosis prior to grafting and ensuring the consumption of
Cryptosporidium-free water to patients when they are in highly immunocompromised states
[84].
Immunocompetent individuals affected by outbreaks
Outbreaks of cryptosporidiosis occur regularly worldwide with the largest recorded event in
history having taken place in Wisconsin, United States, in 1993 (an estimated 400,000 affected)
[85,86]. More than 600 outbreaks were reported in the US, England, and Wales from 2009 to
2017 [87,88]. Transmission in this context occurs mostly from recreational water exposure,
animal contact, person-to-person exposure (e.g., in childcare settings), and foodborne routes.
In the US, the number of reported cryptosporidiosis outbreaks has increased more than 10%
annually in the past decade [87]. Better detection as a result of new diagnostic capabilities may
be one of the reasons for the recent increases in incidence. Nonetheless, reporting of out-
breaks, along with the numbers of individuals affected in any given outbreak, is generally con-
sidered an underestimate due to surveillance and case-finding constraints [87]. Taking those
limitations into account, one analysis estimated more than a million symptomatic cases each
year in just 3 European countries [89]. Underestimation of outbreaks is likely more pro-
nounced in LMICs because of weak health information systems and the relative inaccessibility
of diagnostics.
PLOS NEGLECTED TROPICAL DISEASES Cryptosporidiosis therapies: Use-case scenarios
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009057 March 11, 2021 7 / 20
Cryptosporidium-specific therapy could potentially address acute disease in outbreak situa-
tions and prevent chronic complications. While cryptosporidiosis in immunocompetent indi-
viduals is usually self-limiting, it is more likely to persist compared with other enteric
pathogens and in a minority of cases leads to hospitalization or even death [87,90]. In a Swed-
ish outbreak beginning in 2010 that affected approximately 50,000 people, 35% of adult
patients missed work for an average of 4 days to care for either themselves or their children
[91]. As regards potential chronic complications, long-term follow-up of patients indicates the
possibility of gastrointestinal or joint systems persisting at 1 or 2 years after acute infection;
also, some patients had later been diagnosed with irritable bowel syndrome [92–95]. It is not
clear whether the pathophysiology of chronic symptoms results from persistent or recurrent
Cryptosporidium infection or true postinfectious sequelae (e.g., immunologically mediated).
Future studies are needed to better understand the incidence and nature of chronic sequelae
and whether timely and adequate treatment of acute infection may be preventative.
Current treatment for cryptosporidiosis: Nitazoxanide
Nitazoxanide, approved by the US Food and Drug Administration in 2002, remains the only
licensed medicine for treating cryptosporidiosis [102,103]. It was initially approved for use in
children aged 1 to 11 years of age, and in 2004 was also licensed for older children and adults
[103]. Nitazoxanide is a synthetic antiparasitic agent with broad in vitro parasitistatic activity
against a variety of protozoa and helminths [102]. It is administered orally, heat stable, and
generally well tolerated with reports of mild gastrointestinal side effects and occasional yellow
discoloration of sclerae (which can, incidentally, cause alarm in patients who mistake that sign
for jaundice) [104].
In protozoa, nitazoxanide inhibits the anaerobic energy metabolism enzyme pyruvate-fer-
redoxin oxidoreductase, though it is suspected that the drug’s mechanism of action (MOA)
may also include other pathways [102]. The dependence of the efficacy of nitazoxanide on
immune status suggests that its MOA may require a contribution from host immunity. Nita-
zoxanide amplifies host cell antiviral responses, notably interferons [105,106]. If the effect of
nitazoxanide is mediated largely through interferons, it would be expected to be less efficacious
when Th1 immunity is dysfunctional, as CD4 and NK cell function is required for parasite
clearance [107], which could be a factor in nitazoxanide’s poor efficacy in HIV infection [11].
Several studies have shown nitazoxanide to significantly improve clinical response and to
reduce the duration of diarrhea and oocyst shedding in immunocompetent adults and chil-
dren with cryptosporidiosis [108,109]. Two randomized, placebo-controlled trials informed
the regulatory approval of nitazoxanide and showed clinical response rates between 56% and
88% in immunocompetent adults and children compared to a placebo effect of 23% to 44%
[10,108]. In these studies, parasitological clearance occurred in 52% to 75% of patients treated
with nitazoxanide compared to 14% to 24% in patients treated with placebo [10,108].
In contrast to its effectiveness in immunocompetent individuals, the activity of nitazoxa-
nide against cryptosporidiosis appears to be poor in acutely malnourished children, although
data are limited. The most commonly cited study took place nearly 20 years ago in Zambia in
which 25 HIV–negative, malnourished children with cryptosporidiosis were treated with a
3-day course of nitazoxanide; only 56% experienced resolution of diarrhea and 52% demon-
strated oocyst clearance [10]. It has been theorized that the weakened immune system in chil-
dren with malnutrition contributes to their inability to respond to nitazoxanide therapy [110].
In HIV–positive patients, nitazoxanide appears to lack efficacy altogether. A systematic
review conducted in 2005 yielded 2 placebo-controlled trials that examined the efficacy of nita-
zoxanide in PLWHA in Mexico and Zambia. A meta-analysis of these studies showed that
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nitazoxanide failed to significantly reduce the duration and frequency of Cryptosporidium-
associated diarrhea in immunocompromised patients and did not significantly affect oocyst
clearance [99]. These findings are consistent with subsequent placebo-controlled trials in
Egypt and Zambia [11,111].
In summary, evidence suggests that, with regard to treatment of cryptosporidiosis, use of
nitazoxanide is limited in 3 areas in particular: It is not approved in infants under age 1 year, it
is poorly effective in malnourished children, and it is ineffective in patients with HIV. There
may be the opportunity to explore the use of nitazoxanide in combination with new anti-Cryp-
tosporidium therapeutics should they become available.
Treatment settings: Practical considerations
Treatment settings
Diarrhea-related mortality in children under age 5 is highest in LMICs, and therefore, it is par-
ticularly urgent to assure safe and effective treatment options in those regions for patient
groups that are known to be at high risk (Table 2). Disease-specific therapy would ideally be
available wherever young children with diarrhea receive medical care, including at primary-,
secondary-, and tertiary-level facilities. There are also clear needs for reliable access to anti-
Cryptosporidium therapies at nutritional rehabilitation and HIV treatment centers. As the
prevalence of Cryptosporidium infection in children is reported to be higher during the rainy
seasons, greater medicine stocks would presumably be needed during those periods [112].
Diagnostic considerations
Ideally, pathogen-specific treatment would be delivered based on the definitive diagnosis of
cryptosporidiosis and reasonable certainty that the enteric presence of Cryptosporidium is
causative to signs and symptoms of disease. Unfortunately, at this time, there are practical
challenges to diagnosing cryptosporidiosis in the low-resource settings where it is most preva-
lent. Microscopy of fecal specimens is relatively inexpensive but relies on technical laboratory
skills and consumables that are unlikely to be routinely available at resource-constrained and/
or peripheral-level health facilities [113]. Immunological assays exist but are more expensive
and complex to perform. PCR assays have been used frequently for research purposes in
LMICs and have high sensitivity and specificity but are also expected to be prohibitively expen-
sive for routine bedside use in resource-limited settings [114]. The clinical interpretability of
PCR for diagnosis is also complicated by mixed infections where multiple organisms are pres-
ent even if some are commensal or not responsible for active disease, a common scenario
affecting up to 40% of children with diarrhea [50,115].
Antigen detection-based tests may be the most feasible approach to diagnosing cryptospo-
ridiosis as part of routine clinical practice in low-resource settings. These assays can be used
without sophisticated laboratories, require minimal training for health workers, and provide
rapid results (often within 30 minutes of obtaining a stool sample). Rapid diagnostic tests
(RDTs) are generally straightforward to deploy at the bedside in developing countries, as evi-
denced by their widespread use for diagnosis of malaria (more than 300 million RDTs for Plas-
modium falciparum are used annually) [116]. There are several commercial RDTs for
Cryptosporidium, and it has been demonstrated they can be used successfully in endemic
regions in Africa and Asia [112,117]. However, though less expensive than immunoassays or
PCR, the cost would likely still need to be substantially reduced to facilitate wide scale use in
LMICs. Costs vary by manufacturer, though one program in Chad reported the cost of RDTs
for Cryptosporidium to be approximately USD$10 per test [112]. For comparison, malaria
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RDTs are free when used in public health facilities in many countries, or otherwise often cost
less than USD$1 [118].
Empiric therapy and mass drug administration
There is a lack of evidence addressing the role of empiric therapy (i.e., treatment of acute diar-
rheal illness without confirmation of cryptosporidiosis diagnosis) or mass drug administration
(MDA; i.e., therapies administered at population scale to asymptomatic individuals at high
risk of infection) for cryptosporidiosis. However, scenarios are plausible where these methods
could be warranted assuming a safe and effective medicine is available at an affordable cost.
For example, in settings where the prevalence of symptomatic cryptosporidiosis is high and
diagnostic tools are poorly available, presumptive treatment with an anti-Cryptosporidium
therapeutic could be envisioned for patients at high risk of severe outcomes. The efficiency of
this approach would presumably be maximized by precisely defining, to the extent possible,
patient groups most likely to be infected. That could be determined, for example, according to
age (e.g., infants), symptoms (e.g., prolonged or persistent watery diarrhea), time of year (e.g.,
wet season), or HIV or nutritional status. One study in progress, involving an Aboriginal pop-
ulation in Australia, is testing the empiric treatment of acute gastroenteritis in children using
nitazoxanide under the hypothesis that children with a variety of enteric pathogens, including
Cryptosporidium, would be safely treated and complications could be avoided [119]. Accumu-
lated data from this study and similar investigations would be needed to provide sufficient jus-
tification to incorporate presumptive therapy into algorithms of care in standard treatment
guidelines.
The population-wide benefits of periodic MDA are well recognized for addressing diseases
such as trachoma, soil-transmitted helminthiasis, and other diseases [120–123]. For malaria,
seasonal chemoprevention is a WHO-recommended practice in areas of high seasonal malaria
transmission that has been implemented in more than 10 Sahelian countries, targeting over 10
million children with sequential monthly courses of presumptive antimalarial treatment
[124,125]. The lessons to be learned from malaria seasonal chemoprevention programs could
potentially help to inform MDA interventions to control cryptosporidiosis in the future,
depending on progress with development of new anti-Cryptosporidium therapeutics. In
cryptosporidiosis, rationale for MDA could stem from the extremely high rates of infection
that have been observed in some patient groups (e.g., 97% of children in semi-urban slums in
India were found to have acquired Cryptosporidium by age 3) [126], combined with emerging
evidence, discussed above, concerning the potential role of cryptosporidiosis in growth falter-
ing. Nitazoxanide has previously been proposed as an empiric treatment of presumed crypto-
sporidiosis and/or MDA, while acknowledging the research gaps that exist in efficacy and
optimal dosing, cost, and potential development of drug resistance [127]. An ongoing study in
Tanzania is assessing the impact of routine nitazoxanide administration (along with other anti-
microbials) on linear growth in children [128]. As is the case with empiric therapy for acute
disease, more data would be needed to inform the safety and utility of this practice with an
ideal anti-Cryptosporidium therapeutic.
The future of anti-Cryptosporidium therapeutics
Ideal characteristics of an anti-Cryptosporidium therapeutic
An anti-Cryptosporidium therapeutic that is highly effective in the patient populations known
to be at high risk of disease would constitute a critical addition to the limited interventions cur-
rently available for the investigation and treatment of diarrheal diseases. The ideal target prod-
uct profile for a novel anti-Cryptosporidium agent has been previously described [129,130].
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Briefly, the product should be safe and effective, particularly among populations most affected
by the disease and thus licensed for use in children from 3 months of age onwards in addition
to malnourished children and immunocompromised patients; be presented in a dosage form
that is suitable for administration to young children; be available in a heat-stable formulation;
be affordable; and have a simple dosage regimen to facilitate its use in low-resource settings
[29,129,130]. In addition, it should be parasiticidal against both C. hominis and C. parvum
leading to at least 95% reduction in oocyst shedding and resolution of diarrheal symptoms
(i.e., “cure”) without any unmanageable safety risks [129].
Anti-Cryptosporidium therapeutics in the pipeline
Despite its high burden and clinical impact, cryptosporidiosis remains an underappreciated
global health concern, and antiparasitic treatment options are suboptimal. Several drug candi-
dates (including the anticoccidial agent letrazuril, diclazuril, and interleukin-12) were tested in
early phase clinical trials for the treatment of cryptosporidiosis in PLWHA in the early 2000s
with limited success [131,132]. Similarly, the repurposing of a large number of medicines
(including azithromycin, clofazimine, paromomycin, rifamycin, spiramycin, and HIV protease
inhibitors) has been explored in the management of PLWHA affected by cryptosporidiosis,
but as yet without sufficient clinical success [114,129,133–135]. To our knowledge, there has
been no effort to identify parenteral anti-Cryptosporidium preparations that could be used to
address extraintestinal disease.
In recent years, drug discovery research has focused on discovering novel compounds
active against Cryptosporidium spp. Recent achievements in this area give cause for hope with
diverse new chemical entities (NCEs) including Cryptosporidium lipid kinase PI(4)K inhibitors
[136], bumped kinase inhibitors of CpCDPK1 [137], lysine tRNA synthetase (KRS) inhibitors
[138], benzoxaboroles (e.g., AN7973) [139], a cleavage and polyadenylation specificity factor 3
(CPSF3) inhibitor [140], bicyclic azetidines phenylalanyl-tRNA synthetase inhibitors [141], a
piperazine-based compound (MMV665917) [142], a choline-based phospholipid VB-201
[143], and other novel phenotypic screening hits [144]. Most of these NCEs have demonstrated
desirable in vitro anti-Cryptosporidium activity and in vivo efficacy in immunocompromised
mouse models in reducing fecal oocyst burden. Furthermore, several compounds, including
BKI-1369 [145], KDU731 [136], MMV6659917, and AN7973 [139], have demonstrated resolu-
tion of diarrheal symptoms in neonatal calf models, a clinical model of cryptosporidiosis that
closely resembles human infection. These promising preclinical candidates and other com-
pounds described in the literature have largely demonstrated desired in vitro and in vivo anti-
Cryptosporidium activity as defined by the target product profile [129,130]. However, further
in vivo safety and pharmacological characterization are warranted, and none of these com-
pounds have yet entered human trials.
Conclusion
Emerging data is bringing the true burden of disease imposed by cryptosporidiosis into
sharper focus. There is imperative now to ensure the successful translation of evidence and
experience into actionable guidance for health workers to improve outcomes for patients. The
only approved therapy for cryptosporidiosis appears to have important limitations for use in
the 3 patient populations in LMICs for which an effective anti-Cryptosporidium therapeutic is
urgently needed: young children aged 0 to 2 years, malnourished children aged 0 to 5 years,
and PLWHA. Crisply defining the challenges to adequately detecting and treating cryptospo-
ridiosis in these patient populations will be necessary to pragmatically overcome current clini-
cal management barriers. At the same time, helping to educate global stakeholders about the
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newly appreciated burden of cryptosporidiosis will presumably aid advocacy efforts to support
drug and vaccine discovery. Bolstered by recent accomplishments in early drug discovery, an
urgently needed drug against pediatric cryptosporidiosis is a compelling vision in the near
future through concerted collaborative efforts among clinicians, researchers, industry, and
funding agencies in global health. Ideally, a virtuous cycle will be set in motion whereby the
introduction of novel therapeutics would serve immediate clinical needs while helping to raise
public health awareness about cryptosporidiosis and spur further innovation for disease man-
agement in areas of diagnostics, drugs, vaccines, and national disease prevention and control
programs.
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44. Acácio S, Mandomando I, Nhampossa T, Quintó L, Vubil D, Sacoor C, et al. Risk factors for death
among children 0–59 months of age with moderate-to-severe diarrhea in Manhiça district, southern
Mozambique. [cited 2020 Aug 31]. https://doi.org/10.1186/s12879-019-3948-9 PMID: 30987589
45. Prendergast AJ, Kelly P. Interactions between intestinal pathogens, enteropathy and malnutrition in
developing countries. Curr Opin Infect Dis. 2016; 29:229–36. https://doi.org/10.1097/QCO.
0000000000000261 PMID: 26967147
46. Bartelt LA, Lima AAM, Kosek M, Peñataro Yori P, Lee G, Guerrant RL. “Barriers” to Child Develop-
ment and Human Potential: The Case for Including the “Neglected Enteric Protozoa” (NEP) and Other
Enteropathy-Associated Pathogens in the NTDs. PLoS Negl Trop Dis. 2013; 7:e2125. https://doi.org/
10.1371/journal.pntd.0002125 PMID: 23593514
47. Alam NH, Hamadani JD, Dewan N, Fuchs GJ. Efficacy and safety of a modified oral rehydration solu-
tion (ReSoMaL) in the treatment of severely malnourished children with watery diarrhea. J Pediatr.
2003; 143:614–9. https://doi.org/10.1067/S0022-3476(03)00500-6 PMID: 14615732
48. Kumar R, Kumar P, Aneja S, Kumar V, Rehan HS. Safety and efficacy of low-osmolarity ORS vs. mod-
ified rehydration solution for malnourished children for treatment of children with severe acute malnutri-
tion and diarrhea: A randomized controlled trial. J Trop Pediatr. 2015; 61:435–41. https://doi.org/10.
1093/tropej/fmv054 PMID: 26314308
49. Amadi B, Kelly P, Mwiya M, Mulwazi E, Sianongo S, Changwe F, et al. Intestinal and systemic Infec-
tion, HIV, and mortality in Zambian children with persistent diarrhea and malnutrition. J Pediatr Gastro-
enterol Nutr. 2001; 32:550–4. https://doi.org/10.1097/00005176-200105000-00011 PMID: 11429515
50. Akpakpo B, Souley H, Ouattara A et al. Qualitative molecular diagnostics may improve medical man-
agement of hospitalized severely malnourished children with diarrhea: analysis from Hoptial de l’Amitie
Tchad-Chine, N’djamena, Chad. Am Soc Trop Med Hygeine 2016 Annu Meet. Available: https://www.
astmh.org/ASTMH/media/Documents/Abstracts-1501-1939-and-Author-Index-ASTMH-2016-Annual-
Meeting-Abstract-Book.pdf
PLOS NEGLECTED TROPICAL DISEASES Cryptosporidiosis therapies: Use-case scenarios
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009057 March 11, 2021 14 / 20
51. Tumwine JK, Kekitiinwa A, Nabukeera N, Akiyoshi DE, Rich SM, Widmer G, et al. Cryptosporidium
parvum in children with diarrhea in Mulago Hospital, Kampala, Uganda. Am J Trop Med Hyg. 2003;
68: 710–5. Available. http://www.ncbi.nlm.nih.gov/pubmed/12887032. PMID: 12887032
52. Tickell KD, Sharmin R, Deichsel EL, Lamberti LM, Walson JL, Faruque ASG, et al. The effect of acute
malnutrition on enteric pathogens, moderate-to-severe diarrhoea, and associated mortality in the
Global Enteric Multicenter Study cohort: a post-hoc analysis. Lancet Glob Health; 8:e215–24. https://
doi.org/10.1016/S2214-109X(19)30498-X PMID: 31981554
53. Mondal D, Haque R, Sack RB, Kirkpatrick BD, Petri WA. Attribution of malnutrition to cause-specific
diarrheal illness: Evidence from a prospective study of preschool children in Mirpur, Dhaka. Bangla-
desh Am J Trop Med Hyg. 2009; 80:824–6. https://doi.org/10.4269/ajtmh.2009.80.824 PMID:
19407131
54. Bitilinyu-Bangoh J, Voskuijl W, Thitiri J, Menting S, Verhaar N, Mwalekwa L, et al. Performance of
three rapid diagnostic tests for the detection of Cryptosporidium spp. and Giardia duodenalis in chil-
dren with severe acute malnutrition and diarrhoea. Infect Dis Poverty. 2019; 8:1–8. https://doi.org/10.
1186/s40249-018-0513-5 PMID: 30626428
55. Opintan JA, Newman MJ, Ayeh-Kumi PF, Affrim R, Gepi-Attee R, Sevilleja JEAD, et al. Pediatric diar-
rhea in Southern Ghana: Etiology and association with intestinal inflammation and malnutrition. Am J
Trop Med Hyg. 2010; 83:936–43. https://doi.org/10.4269/ajtmh.2010.09-0792 PMID: 20889896
56. Jain A, Shah D, Das S, Saha R, Gupta P. Aetiology and outcome of acute diarrhoea in children with
severe acute malnutrition: a comparative study. Public Health Nutr. 2019:1–6. https://doi.org/10.1017/
S1368980019003069 PMID: 31699164
57. Cegielski JP, Ortega YR, McKee S, Madden JF, Gaido L, Schwartz DA, et al. Cryptosporidium, Enter-
ocytozoon, and Cyclospora Infections in Pediatric and Adult Patients with Diarrhea in Tanzania. Clin
Infect Dis. 1999; 28:314–21. https://doi.org/10.1086/515131 PMID: 10064250
58. Quihui-Cota L, Lugo-Flores CM, Ponce-Martinez JA, Morales-Figueroa GG. Cryptosporidiosis: A
neglected infection and its association with nutritional status in schoolchildren in northwestern Mexico.
J Infect Dev Ctries. 2015; 9:878–83. https://doi.org/10.3855/jidc.6751 PMID: 26322881
59. World Health Organization. Reducing stunting in children: equity considerations for achieving the
Global Nutrition Targets 2025. 2018.
60. Harper KM, Mutasa M, Prendergast AJ, Humphrey J, Manges AR. Environmental enteric dysfunction
pathways and child stunting: A systematic review. Kosek M, editor. PLoS Negl Trop Dis. 2018; 12:
e0006205. https://doi.org/10.1371/journal.pntd.0006205 PMID: 29351288
61. Yones D, Zaghlol K, Abdallah A, Galal L. Effect of enteric parasitic infection on serum trace elements
and nutritional status in upper Egyptian children. Tropenmed Parasitol. 2015; 5:29. https://doi.org/10.
4103/2229-5070.145581 PMID: 25709950
62. Korpe PS, Haque R, Gilchrist C, Valencia C, Niu F, Lu M, et al. Natural History of Cryptosporidiosis in
a Longitudinal Study of Slum-Dwelling Bangladeshi Children: Association with Severe Malnutrition.
Kang G, editor. PLoS Negl Trop Dis. 2016; 10: e0004564. https://doi.org/10.1371/journal.pntd.
0004564 PMID: 27144404
63. Steiner KL, Ahmed S, Gilchrist CA, Burkey C, Cook H, Ma JZ, et al. Species of cryptosporidia causing
subclinical infection associated with growth faltering in rural and Urban Bangladesh: A birth cohort
study. Clin Infect Dis. 2018; 67:1347–55. https://doi.org/10.1093/cid/ciy310 PMID: 29897482
64. Mølbak K, Andersen M, Aaby P, Højlyng N, Jakobsen M, Sodemann M, et al. Cryptosporidium infec-
tion in infancy as a cause of malnutrition: a community study from Guinea-Bissau, west Africa. Am J
Clin Nutr. 1997; 65: 149–52. Available: http://www.ncbi.nlm.nih.gov/pubmed/8988927 https://doi.org/
10.1093/ajcn/65.1.149 PMID: 8988927
65. Checkley W, Epstein LD, Gilman RH, Black RE, Cabrera L, Sterling CR. Effects of Cryptosporidium
parvum infection in Peruvian children: growth faltering and subsequent catch-up growth. Am J Epide-
miol. 1998; 148: 497–506. Available: http://www.ncbi.nlm.nih.gov/pubmed/9737562 https://doi.org/10.
1093/oxfordjournals.aje.a009675 PMID: 9737562
66. Korpe PS, Valencia C, Haque R, Mahfuz M, McGrath M, Houpt E, et al. Epidemiology and Risk Fac-
tors for Cryptosporidiosis in Children From 8 Low-income Sites: Results From the MAL-ED Study. Clin
Infect Dis. 2018; 67:1660–9. https://doi.org/10.1093/cid/ciy355 PMID: 29701852
67. Rogawski ET, Liu J, Platts-Mills JA, Kabir F, Lertsethtakarn P, Siguas M, et al. Use of quantitative
molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in
children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study. Lan-
cet Glob Health. 2018; 6:e1319–28. https://doi.org/10.1016/S2214-109X(18)30351-6 PMID:
30287125
68. Niehaus MD, Moore SR, Patrick PD, Derr LL, Lorntz B, Lima AA, et al. Early childhood diarrhea is
associated with diminished cognitive function 4 to 7 years later in children in a northeast Brazilian
PLOS NEGLECTED TROPICAL DISEASES Cryptosporidiosis therapies: Use-case scenarios
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009057 March 11, 2021 15 / 20
shantytown. Am J Trop Med Hyg. 2002; 66: 590–3. Available: http://www.ncbi.nlm.nih.gov/pubmed/
12201596 https://doi.org/10.4269/ajtmh.2002.66.590 PMID: 12201596
69. Guerrant DI, Moore SR, Lima AA, Patrick PD, Schorling JB, Guerrant RL. Association of early child-
hood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven
years later in a poor urban community in northeast Brazil. Am J Trop Med Hyg. 1999; 61: 707–13.
Available: http://www.ncbi.nlm.nih.gov/pubmed/10586898 https://doi.org/10.4269/ajtmh.1999.61.707
PMID: 10586898
70. Mwachari C, Batchelor BIF, Paul J, Waiyaki PG, Gilks CF. Chronic diarrhoea among HIV-infected
adult patients in Nairobi. Kenya J Infect. 1998; 37:48–53. https://doi.org/10.1016/s0163-4453(98)
90561-8 PMID: 9733379
71. Colford JM, Tager IB, Hirozawa AM, Lemp GF, Aragon T, Petersen C. Cryptosporidiosis among
Patients Infected with Human Immunodeficiency Virus: Factors Related to Symptomatic Infection and
Survival. Am J Epidemiol. 1996; 144:807–16. https://doi.org/10.1093/oxfordjournals.aje.a009015
PMID: 8890659
72. UNAIDS. UNAIDS Data 2018. 2018. Available: https://www.unaids.org/sites/default/files/media_
asset/unaids-data-2018_en.pdf
73. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national
incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries
and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study. Lancet.
2017; 2018:1789–858. https://doi.org/10.1016/S0140-6736(18)32279-7 PMID: 30496104
74. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging
and immunological classification of HIV-related disease in adults and children. World Health. 2007.
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